A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.